Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Effect of atorvastatin on preparation of drug for treating pulmonary hypertension

A technology of atorvastatin and pulmonary arterial hypertension, applied in the field of action of drugs, can solve problems such as reduction of systemic circulation pressure

Inactive Publication Date: 2014-04-02
邢西迁
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, the drugs for the treatment of pulmonary arterial hypertension mainly include prostacyclin analogs, phosphodiesterase inhibitors, endothelin receptor antagonists and inhaled nitric oxide, but these drugs are only effective for some patients with pulmonary arterial hypertension, and can reduce systemic circulation pressure side effects
However, there is no report about whether statins affect the expression of NF-kB in the lung tissue of rats with pulmonary arterial hypertension.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Effect of atorvastatin on preparation of drug for treating pulmonary hypertension
  • Effect of atorvastatin on preparation of drug for treating pulmonary hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0106] The preparation of embodiment 1 tablet of the present invention

[0107] a) The preparation formula is:

[0108] Atorvastatin 100g, starch 300g, calcium stearate 5g

[0109] b) Preparation method:

[0110] 100 g of the above-mentioned atorvastatin and 300 g of starch are fully mixed, added with starch paste to make a suitable soft material, granulated, dried at 100 degrees, granulated, added with calcium stearate, compressed into 1000 tablets.

[0111] The dosage of the medicament of the present invention is 1 tablet / day as a starting dose, and the dosage range is 1-6 tablets / day, and it can be taken orally once a day.

Embodiment 2

[0112] The preparation of embodiment 2 capsules of the present invention

[0113] a) The preparation formula is atorvastatin 200g, lactose 350g, oxidized vegetable oil 3g

[0114] b) Preparation method:

[0115] 200g of atorvastatin and 350g of lactose are fully mixed, added with starch paste to make a suitable soft material, granulated, dried at 100 degrees, granulated, added with hydrogenated vegetable oil, mixed evenly, filled into capsules to make 1000 capsules.

[0116] The dosage of the medicine of the present invention is 1 capsule / day, the dosage range is 1-3 capsules / day, and it can be taken orally once a day.

Embodiment 3

[0117] The preparation of embodiment 3 granules of the present invention

[0118] a) The preparation formula is:

[0119] Atorvastatin 200g, sucrose 800g

[0120] b) Preparation method:

[0121] 200 g of the above-mentioned atorvastatin and 800 g of sucrose are fully mixed, added with water to make a suitable soft material, granulated, dried at 100 degrees, granulated, and bagged to make 1000 bags of granules.

[0122] The dosage of the medicine of the present invention is 1 bag / day, the dose range is 1-3 bags / day, and it can be taken orally once a day.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a new use of a drug, and specifically relates to an effect of atorvastatin on preparation of a drug for treating pulmonary hypertension. The invention discovers for the first time that atorvastatin is capable of alleviating MCT (Monocrotaline)-induced pulmonary inflammation, and inhibiting pulmonary vascular remodeling, pulmonary artery rising and right ventricular hypertrophy without affecting the body circulating pressure; NF-kB is possible to play an important role in the MCT-induced pulmonary hypertension; the atorvastatin is capable of inhibiting the inflammatory reaction by reducing the expression of the MCT-induced pulmonary hypertension lung tissue NF-kB, and is capable of reducing pulmonary vascular remodeling and inhibiting the pulmonary artery high pressure rising; therefore, the atorvastatin can be applied to preparation of the drug for treating the pulmonary hypertension.

Description

technical field [0001] The present invention relates to a new application of medicine, in particular, relates to the effect of atorvastatin in the preparation of medicine for treating pulmonary arterial hypertension. Background technique [0002] Pulmonary hypertension is a common and serious complication of chronic lung disease, characterized by increased pulmonary vasoconstriction reactivity and pulmonary vascular structural remodeling. Its formation mechanism has not yet been fully explained. Current studies have shown that the enhanced responsiveness of pulmonary vasoconstriction is caused by vascular endothelial dysfunction. The imbalance between vasodilation substances such as nitric oxide and vasoconstrictor substances such as endothelin is a feature of vascular endothelial dysfunction; while pulmonary vascular structure reconstruction is mostly These factors stimulate the proliferation of pulmonary vascular smooth muscle cells, the increase of extracellular matrix c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/40A61P11/00A61P29/00
Inventor 邢西迁杨姣吴尚洁吴绪伟李艳丽张鲸旋肖谊
Owner 邢西迁
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com